3 Top Biotech Stocks to Buy Right Now
These three biotech stocks should be outstanding long-term growth vehicles.
Mirati Therapeutics
MRTX
MRTX
$103.57
-$1.98
-1.9%
BATS BZX Real Time Price as of July 15, 2019, 4:00 p.m. EDT
View Interactive MRTX Charts
Mirati Therapeutics, Inc.
News & Analysis: Mirati Therapeutics
Read This Before You Buy Any New Cancer Drug Stocks
Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.
Here's Why Mirati Therapeutics Is Jumping Today
It looks like a target considered undruggable is actually within reach.
Here's Why Mirati Therapeutics Is Surging Today
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
Here's Why Mirati Therapeutics Jumped 55.8% in January
Investors cheered the biotech's plans to move its lead candidate forward.
Why Mirati Therapeutics Inc. Is Plunging Today
Shares tumbled after the company reported clinical data from an important phase 2 trial. Here's what investors need to know.
3 Biotech Stocks With Major Incoming Catalysts
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
Here's Why Mirati Therapeutics, Inc. Is Rising Today
Wall Street cheers after the company announced favorable terms from a just-announced capital raise. Here's what investors need to know.
Can These Top-Performing Biotech Stocks Keep Climbing?
Over the past year, these two biotech stocks outperformed nearly all their peers. Can they keep it going?
Why Sturm Ruger, Mirati Therapeutics, and Barracuda Networks Slumped Today
Even though the market was higher, these stocks missed out. Find out why.
